CoronaryAtlas logo
CoronaryAtlas
Lysophosphatidylcholine
Pathway / Lipid retention & oxidation

Lysophosphatidylcholine

lipid

Lysophosphatidylcholine, a bioactive lipid species derived from lipoprotein remodeling, promotes atherosclerosis and altered lipid homeostasis in Type 1 MI.

Pathway placement
Cascade stepLipid retention & oxidation
Confidencemedium
RationaleBioactive lipid metabolite; altered in dyslipidemia and atherosclerosis; membrane disruption and inflammatory mediator.
Also acts inVascular inflammation
Druggability
Not assessed (no mapped human gene target).

Type I vs Type II discrimination

ScoresLow-confidence (proxy)
R — rupture / Type-I
56
C — confounder / Type-II
75
A — assay feasibility
40
E — evidence strength
29
T1DI (composite)
5
Specificity differential (R−C)-19.5
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma (EDTA to limit oxidation)
Collection tube
K2/K3-EDTA (lavender-top) · Serum separator (gold/red-top, SST)
Method / principle
LC-MS/MS lipidomics (targeted or shotgun)
Reagent / substrate
Deuterated lipid-class internal standards; MS/MS transitions
Platform
LC-MS/MS
Turnaround · availability
Research · Research-only

Literature evidence(23)